Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07205081
PHASE1

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Sponsor: Attovia Therapeutics Inc

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

72

Start Date

2025-10-22

Completion Date

2026-10

Last Updated

2026-05-28

Healthy Volunteers

Yes

Interventions

DRUG

ATTO-3712

ATTO-3712

DRUG

Placebo

Placebo preparation to match ATTO-3712 dose

Locations (4)

Attovia Clinical Site 203

Encinitas, California, United States

Attovia Clinical Site 202

Saint Joseph, Missouri, United States

Attovia Clinical Site 102

Peterborough, Ontario, Canada

Altasciences

Montreal, Quebec, Canada